Last reviewed · How we verify
CCX282-B
At a glance
| Generic name | CCX282-B |
|---|---|
| Sponsor | Amgen |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Phase II Study of CCX282-B in Patients With Celiac Disease (PHASE2)
- A Study to Evaluate the Efficacy and Safety of CCX282-B in Subjects With Moderate to Severe Crohn's Disease (PHASE2)
- Safety and Activity Study of an Oral Medication to Treat Moderate to Severe Crohn's Disease (PHASE2)
- An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease (PHASE3)
- A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease (PHASE3)
- Open-Label Extension Study of GSK1605786A (PHASE3)
- GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease (PHASE3)
- A Study to Assess the Relative Bioavailability of Four New Formulations of GSK1605786 in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CCX282-B CI brief — competitive landscape report
- CCX282-B updates RSS · CI watch RSS
- Amgen portfolio CI